FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Occident 10.1 onn 4 of 1 onn 5	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Monia Brett P (Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC.					3. D	Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ISIS] Date of Earliest Transaction (Month/Day/Year) 06/08/2015										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) 5VP, Antisense Drug Discovery				
(Street) CARLSE		A state)	92010 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	e) X Form: Form: Perso	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			ction	2A Ex r) if a	ecurities Acq 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (4. Securit	Osed of, or Benefi 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amou Securiti Benefic Owned	int of es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D) Pri		Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common	Stock			06/08/	2015		06/08	3/2015	M ⁽¹⁾		7,600(1	1)	Α	\$10.2	10.29 12,026 D					
Common	Stock			06/08/	2015	(06/08	3/2015	S ⁽¹⁾		7,600(1	1)	D	\$66.2	21 4,426 D					
		Т	able II -								osed of converti				/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (I B)		n of		6. Date E Expiratio (Month/D	n Dat		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa		Expiration Date	Title		Amount or Number of Shares						
Employee Stock Option (right to	\$10.29	06/08/2015	06/08/	2015	М			7,600	01/03/20	15	01/02/2018	Com		7,600	\$0	0		D		

Explanation of Responses:

1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/8/2015.

Remarks:

/s/Brett P. Monia

06/10/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.